Janux Therapeutics (JANX) Liabilities and Shareholders Equity (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.15% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $4.1 billion, a 16.81% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 5.65% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.0 billion, up from $1.0 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for JANX reached as high as $1.1 billion in Q4 2024 and fell as low as $341.5 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $660.6 million across 5 years, with a median of $689.0 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity slipped 11.38% in 2023 and jumped 179.05% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $364.0 million in 2022, then gained by 4.5% to $380.4 million in 2023, then soared by 179.05% to $1.1 billion in 2024, then dropped by 5.65% to $1.0 billion in 2025, then climbed by 2.66% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.